Home / Platform
Our platform
Advance with confidence through a drug discovery platform built to generate reproducible, decision-grade evidence in intact human tissue, supporting clearer high-stakes pipeline decisions.
Stop modeling. Start testing
Leveraging precision-cut tissue slices (PCTS) cultured in our unique, patented bioreactor technology, our platform supports advanced molecular and tissue-level analysis in intact and viable human tissue.
With assays standardised into a robust, reproducible research platform, you benefit from the ability to assess tissue health and drug response across extended study durations while gaining high-fidelity data at scale.
Advanced molecular and tissue-level analysis
Delivering decision-grade impact
Our platform provides the ultimate protection for your clinical transition by replacing proxy assumptions with definitive biological reality.
In close partnership with your team, we design tailored experiments to evaluate the safety, target engagement, efficacy and mode of action of your novel interventions in complex, living human tissue.
Leveraging advanced liquid handling robotics and AI-powered data analysis, our platform transforms data into a scalable, reproducible and decision-grade evidentiary system.
Related resources
Discover more insights on how FibroFind’s proprietary bioreactor platform sustains intact, viable human tissue to generate stronger human-relevant evidence across preclinical development.
Poster
Combination of an Acetyl-Coenzyme A Carboxylase Inhibitor and Fibroblast Growth Factor-19 Reduced Tissue Triglyceride Content and Fibrosis in Human Precision-Cut Liver Slices
See how combining ACC inhibition with FGF19 reduced triglyceride accumulation and fibrosis in human precision-cut liver slices.
The evidence your program demands
Speak to our team about your program.